Last reviewed · How we verify
umbilical cord-mesenchymal stem cells
Umbilical cord-mesenchymal stem cells promote tissue repair and regeneration through immunomodulation, anti-inflammatory effects, and differentiation into specialized cell types.
Umbilical cord-mesenchymal stem cells promote tissue repair and regeneration through immunomodulation, anti-inflammatory effects, and differentiation into specialized cell types. Used for Tissue repair and regeneration (specific indications not clearly defined in public literature).
At a glance
| Generic name | umbilical cord-mesenchymal stem cells |
|---|---|
| Also known as | UC-MSCs |
| Sponsor | General Hospital of Shenyang Military Region |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine |
| Phase | FDA-approved |
Mechanism of action
These allogeneic stem cells derived from umbilical cord tissue exert therapeutic effects by secreting immunomodulatory cytokines, reducing inflammatory responses, and differentiating into various cell lineages to replace damaged tissue. They can engraft into injured areas and promote angiogenesis and tissue remodeling through paracrine mechanisms.
Approved indications
- Tissue repair and regeneration (specific indications not clearly defined in public literature)
Common side effects
- Infusion-related reactions
- Infection risk
- Immune rejection
Key clinical trials
- The Safety and Efficacy of XytriX in the Treatment of Knee Osteoarthritis (PHASE1, PHASE2)
- Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis (PHASE3)
- To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS). (PHASE3)
- Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction (PHASE2, PHASE3)
- Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment (PHASE1)
- The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease (PHASE1, PHASE2)
- Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease (PHASE1, PHASE2)
- Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: